Biotech tests very important support zoneThe Biotech bubble bursting hits Nasdaq and makes it the weaker link in the indices chain.
It all began when $IBB broke below 360$, closing below its Fast SMA line, providing the bearish signal by breaking down the weekly uptrend line (see point 1)
August's declines lead $IBB to re-test another weekly uptrend line and the 300$ support zone - This created a rally back towards 360$ that ended when the price was rejected by the 360 structure and the Fast SMA line that flipped roles to resistance.
Now, three week's later, $IBB is re-testing the 300$ (currently inside the zone). It is also re-testing the same uptrend that helped it during August.
That is a critical zone for Biotech. The next support zone is near 260$ and below it, the 200 weeks MA waits near 230$.
If $IBB will manage to find the necessary support inside 280-300$ again, it could lead to a rally towards its 50 weeks MA line that should turn to resistance now.
A close above 300$ could be a bullish confirmation signal that we are heading there.
Follow me on TradingView
Follow my blog: marketzone.tumblr.com
Subscribe to my newsletters: goo.gl
Biotechnology
Short biotechnology again near trend line resistance Biotech bubble has burst.
Every rallies are to be sold, and despite the euphoria/new highs in S&P and Nasdaq have barely registered a decent retracement in the biotech sector..
Here's a larger picture of how far biotechs have went since 2008:
The uptrend in S&P is limited, and it will only be a matter of time before it collapses off this rising wedge. However it is also risky to go against Janet Yellen (FED) with unlimited cash in its balance sheet. A short on a specific sector would be a much safer bet.
-------------------
I'm long on ZBIO (3x short biotech ETF) at 22.51, with a target around $30~40.
#Nasdaq #Biotech It ought to correct overboughtIt ought to correct overbought Nasdaq Biotechnology Index:
The Nasdaq Biotech index has grown about 50 percent since Yellen's valuation comments. Superarando por mucho el desempeño de los indices composite y S&P500, this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index It ought to correct their overbought at least 6% as it has done in later months
www.bloomberg.com
The Seven Reason I Bought GILDI Bought GILD for seven reasons:
(1) Head and Shoulders Pattern (60 min)
(2) Horizontal Support from Left Shoulder ($102.72)
(3) 61.8% Fib level Support @ $102.75
(4) Descending Trend line Support
(5) Long-wicked Hammer found Support at Trend line
(6) Weekly Uptrend
(7) Selling Climax in February 2015
(8) The risk/reward potential is favorable. My reward is based on a daily and weekly chart. So, It is approx. $117.
-ScienceEvolution